Semaglutide 3mg – 30 Capsules

Semaglutide is a derivative of the naturally occurring GLP-1, a peptide known to lower blood sugar levels and enhance insulin secretion. Research shows that Semaglutide may also improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer’s disease. Semaglutide has been shown to significantly decrease appetite by delaying gastric emptying and reducing intestinal motility. Glucagon-Like Peptide-1 (GLP-1) Analog Shown to Stimulate Insulin and Suppress Glucagon Secretion in a Glucose-Dependent Manner.

Semaglutide and GLP-1 Overview

GLP-1, short for glucagon-like-peptide-1 is a short, naturally occurring peptide hormone just 30-31 amino acids in length. Its primary physiologic function is to lower blood sugar levels by naturally enhancing insulin secretion. It also plays roles in protecting beta cell insulin stores by promoting insulin gene transcription and has been linked with neurotrophic effects in the brain and central nervous system. In the GI system, GLP-1 has been shown to significantly decrease appetite by delaying gastric emptying and reducing intestinal motility. Preliminary research has shown impacts of GLP-1 in the heart, fat, muscles, bones, liver, lungs, and kidneys as well.

The primary of GLP-1 research has been in the realm of diabetes treatment/prevention as well as appetite suppression. Secondary research focuses on the potential cardiovascular benefits of the peptide. More recent, and thus less robust, research focuses on the ability of GLP-1 to stave off neurodegenerative disease. This area of study of the peptide has revealed to slow or prevent the accumulation of amyloid beta plaques in the settling of Alzheimer’s disease.

Semaglutide and GLP-1 Research

GLP-1 and Appetite

Research in mouse models suggest that administration of GLP-1 into the brains of mic e can reduce the drive to eat and inhibit food intake. It appears that GLP-1 may actually enhance feelings of satiety, helping individuals to feel fuller and reducing hunger indirectly. Recent clinical studies have shown in mice that twice daily administration of GLP-1 receptor agonists cause gradual linear weight loss. Over a long period, this weight loss is associated with significant improvement in cardiovascular risk factors and reduction in hemoglobin A1C levels, the latter of these being a proxy marker for the severity of diabetes and the quality of blood sugar control attained via treatment.

GLP-1 and Beta Cell Protection

Research in animal models suggests that GLP-1 can stimulate the growth and proliferation of pancreatic beta cells and that it may stimulate the differentiation of new beta cells form progenitors in the pancreatic duct epithelium. Research has also shown that GLP-1 beta cell apoptosis. Taken in sum, these effects tip the usual balance of beta cell growth and death toward growth, suggesting that the peptide may be useful in treating diabetes and in protecting the pancreas against insult that harm beta cells.

In one particular compelling trial, GLP-1 was shown to inhibit the death of beta cells caused by enhanced levels of inflammatory cytokines. In fact, mouse models of type 1 diabetes have revealed that GLP-1 protects islet cells from destruction and may, in fact, be a useful means of preventing onset of type 1 diabetes.

GLP-1 and the Brain

Recent studies suggest that GLP-1 may play an important role in modulating both learning and memory processes in the brain. For example, one study found that injecting rats with GLP-1 led to improved memory function on tests of spatial learning and memory when compared to control animals who were not injected with the hormone. Other studies have found similar results in humans; those who received injections of GLP-1 performed better on cognitive tasks than those who did not receive injections of the hormone. This suggests that increasing levels of GLP-1 may be beneficial for improving overall cognition and brain health.

While more research needs to be done to fully understand how increasing levels of GLP-1 can benefit cognitive processes in humans, there are already some promising findings that suggest this could be a valuable approach for improving overall brain health. In addition to its potential benefits for improving memory function, increasing levels of GLP-1 may also help protect against neurodegenerative diseases like Alzheimer’s disease by reducing inflammation in the brain and promoting neuron growth. Further research will be necessary to fully understand the potential therapeutic benefits of targeting this hormone system in humans, but these initial findings are certainly exciting!

Potential Cardiovascular Benefits of GLP-1

While much of its activity has been focused on glucose metabolism, studies suggest that GLP-1 may also play an important role in cardiovascular health. In one study, researchers found that postprandial plasma GLP-1 was associated with improved arterial stiffness—a marker for cardiovascular disease—in patients with type 2 diabetes who were treated with pioglitazone or sulfonylureas drugs. Another study found that low plasma concentrations of active GLP-1 were associated with higher risk for incident coronary heart disease among individuals without diabetes as well as increased risk for all cause mortality among those with diabetes or impaired glucose tolerance (IGT).